These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 12177583)

  • 21. Remission in schizophrenia: 196-week, double-blind treatment with ziprasidone vs. haloperidol.
    Potkin SG; Weiden PJ; Loebel AD; Warrington LE; Watsky EJ; Siu CO
    Int J Neuropsychopharmacol; 2009 Oct; 12(9):1233-48. PubMed ID: 19419595
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison of ziprasidone and risperidone in the long-term treatment of schizophrenia: a 44-week, double-blind, continuation study.
    Addington DE; Labelle A; Kulkarni J; Johnson G; Loebel A; Mandel FS
    Can J Psychiatry; 2009 Jan; 54(1):46-54. PubMed ID: 19175979
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Dose reduction of high-dose first-generation antipsychotics or switch to ziprasidone in long-stay patients with schizophrenia: A 1-year double-blind randomized clinical trial.
    Bogers JPAM; Schulte PFJ; Broekman TG; Moleman P; de Haan L
    Eur Neuropsychopharmacol; 2018 Sep; 28(9):1024-1034. PubMed ID: 30025751
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 May; 110(1-3):80-9. PubMed ID: 19269791
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A post hoc analysis of negative symptoms and psychosocial function in patients with schizophrenia: a 40-week randomized, double-blind study of ziprasidone versus haloperidol followed by a 3-year double-blind extension trial.
    Stahl SM; Malla A; Newcomer JW; Potkin SG; Weiden PJ; Harvey PD; Loebel A; Watsky E; Siu CO; Romano S
    J Clin Psychopharmacol; 2010 Aug; 30(4):425-30. PubMed ID: 20571437
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ziprasidone vs clozapine in schizophrenia patients refractory to multiple antipsychotic treatments: the MOZART study.
    Sacchetti E; Galluzzo A; Valsecchi P; Romeo F; Gorini B; Warrington L;
    Schizophr Res; 2009 Aug; 113(1):112-21. PubMed ID: 19606529
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ziprasidone in adolescents with schizophrenia: results from a placebo-controlled efficacy and long-term open-extension study.
    Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP
    J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):531-44. PubMed ID: 24111983
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia.
    Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR
    J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: a randomized, double-blind, placebo- and active-controlled trial.
    Loebel A; Cucchiaro J; Sarma K; Xu L; Hsu C; Kalali AH; Pikalov A; Potkin SG
    Schizophr Res; 2013 Apr; 145(1-3):101-9. PubMed ID: 23415311
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intramuscular (IM) ziprasidone 20 mg is effective in reducing acute agitation associated with psychosis: a double-blind, randomized trial.
    Daniel DG; Potkin SG; Reeves KR; Swift RH; Harrigan EP
    Psychopharmacology (Berl); 2001 May; 155(2):128-34. PubMed ID: 11401000
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cost-effectiveness analysis of the prevention of relapse of schizophrenia in the longitudinal study Ziprasidone Extended Use in Schizophrenia (ZEUS).
    Bernardo M; Azanza JR; Rubio-Terrés C; Rejas J
    Actas Esp Psiquiatr; 2007; 35(4):259-62. PubMed ID: 17592789
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effectiveness of switching to ziprasidone for stable but symptomatic outpatients with schizophrenia.
    Weiden PJ; Simpson GM; Potkin SG; O'Sullivan RL
    J Clin Psychiatry; 2003 May; 64(5):580-8. PubMed ID: 12755663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Olanzapine versus ziprasidone: results of a 28-week double-blind study in patients with schizophrenia.
    Breier A; Berg PH; Thakore JH; Naber D; Gattaz WF; Cavazzoni P; Walker DJ; Roychowdhury SM; Kane JM
    Am J Psychiatry; 2005 Oct; 162(10):1879-87. PubMed ID: 16199834
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How dosing of ziprasidone in a state hospital system differs from product labeling.
    Citrome L; Jaffe A; Levine J
    J Clin Psychiatry; 2009 Jul; 70(7):975-82. PubMed ID: 19653974
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ziprasidone in treatment-resistant schizophrenia: a 52-week, open-label continuation study.
    Loebel AD; Khanna S; Rajadhyaksha S; Siu CO; Giller E; Potkin SG
    J Clin Psychiatry; 2007 Sep; 68(9):1333-8. PubMed ID: 17915970
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Ziprasidone plus a mood stabilizer in subjects with bipolar I disorder: a 6-month, randomized, placebo-controlled, double-blind trial.
    Bowden CL; Vieta E; Ice KS; Schwartz JH; Wang PP; Versavel M
    J Clin Psychiatry; 2010 Feb; 71(2):130-7. PubMed ID: 20122373
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
    Gunasekara NS; Spencer CM; Keating GM
    Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Long-term improvement in efficacy and safety after switching to ziprasidone in stable outpatients with schizophrenia.
    Simpson GM; O'Gorman CJ; Loebel A; Yang R
    CNS Spectr; 2008 Oct; 13(10):898-905. PubMed ID: 18955945
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ziprasidone in the short-term treatment of patients with schizoaffective disorder: results from two double- blind, placebo-controlled, multicenter studies.
    Keck PE; Reeves KR; Harrigan EP;
    J Clin Psychopharmacol; 2001 Feb; 21(1):27-35. PubMed ID: 11199944
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Early improvement on antipsychotic treatment as a predictor of subsequent response in schizophrenia: analyses from ziprasidone clinical studies.
    O'Gorman C; Kapur S; Kolluri S; Kane J
    Hum Psychopharmacol; 2011; 26(4-5):282-90. PubMed ID: 21638329
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.